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Abstract Aim: To evaluate the implementation of targeted therapy on overall survival (OS)
in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC).
Methods: All Danish patients with mRCC referred for ﬁrst line treatment with immunother-
apy, TKIs or mTOR-inhibitors between 2006 and 2010 were included. Baseline and outcome
data were collected retrospectively. Prognostics factors were identiﬁed using log-rank tests and
Cox proportional hazard model. Differences in distributions were tested with the Chi-square
test.
Results: 1049 patients were referred; 744 patients received ﬁrst line treatment. From 2006 to
2010 we observed a signiﬁcant increase in the number of referred patients; a signiﬁcant
increase in treated patients (64% versus 75%, P = 0.0188); a signiﬁcant increase in ﬁrst line tar-
geted therapy (22% versus 75%, P < 0.0001); a signiﬁcant increase in second line treatment
(20% versus 40%, P = 0.0104), a signiﬁcant increased median OS (11.5 versus 17.2 months,
P = 0.0435) whereas survival for untreated patients remained unchanged. Multivariate anal-
ysis validated known prognostic factors. Moreover, treatment start years 2008 (HR 0.74,
95% CI, 0.55–0.99; P = 0.0415), 2009 (HR 0.72, 95% CI, 0.54–0.96; P = 0.0277) and 2010
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(HR 0.63, 95% CI, 0.47–0.86; P = 0.0035) compared to 2006, and more than two treatment
lines received for patients with performance status 0–1 (HR 0.76, 95% CI, 0.58–0.99;
P = 0.0397) and performance status 2–3 (HR 0.19, 95% CI, 0.06–0.60; P = 0.0051) were sig-
niﬁcantly associated with longer OS.
Conclusion: This retrospective study documents that the implementation of targeted therapy
has resulted in signiﬁcantly improved treatment rates and overall survival in a complete
national cohort of treated mRCC patients.
 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
Prior to the introduction of targeted therapy with tyro-
sine kinase inhibitors (TKI) and mammalian target of
rapamycin (mTOR) inhibitors, treatment options for
patients with metastatic renal cell carcinoma (mRCC)
were limited. Chemotherapy did not impact overall sur-
vival (OS) and immunotherapy was only given to patients
in good performance status (PS). The introduction of tar-
geted therapy has therefore expanded treatment opportu-
nities. In Denmark, sorafenib became available in 2006
[1], sunitinib [2] and temsirolimus [3] in 2007, everolimus
[4] in 2009, pazopanib [5] in 2010 and axitinib in 2013.
These new drugs were approved due to signiﬁcant
improvements in progression free survival (PFS), but
only temsirolimus has demonstrated a statistically signif-
icant improved OS in poor risk mRCC patients [3].
Cancer treatment in Denmark is free with equal
access to surgery, systemic therapy and palliative care.
Treatment of mRCC is restricted to four centres; there
are no private clinics for systemic cancer treatment.
All Danish citizens are assigned a unique social security
number at birth or immigration and all contacts with the
health system are based on this number. It is therefore
possible to track all patients from diagnosis until date
of death. This gives a unique opportunity to identify
and study a complete national cohort of treated patients
with mRCC and an untreated cohort.
This study assessed the ﬁrst 5 years of the implemen-
tation of targeted therapy in a complete national cohort
of treated patients with mRCC to investigate whether
OS was improved in real-life settings.
2. Patients and methods
2.1. Patient characteristics
Medical oncology treatment for mRCC was centra-
lised at four hospitals in Denmark (Aarhus University
Hospital, Odense University Hospital, University Hos-
pital of Copenhagen Rigshospitalet, and the University
Hospital of Copenhagen Herlev). All patients with
biopsy-proven mRCC referred for medical oncology
treatment between January 1st 2006 and December
31st 2010 were identiﬁed by a National Registry (GS-
Open) and institution databases. Individual medical
records were collected and reviewed. All patients, who
started ﬁrst line treatment with immunotherapy, TKIs,
or mTOR-inhibitors for mRCC, were included. Baseline
clinical and paraclinical data were collected retrospec-
tively. Blood samples were standardised to the treating
hospital’s Upper Level of Normal (ULN) and Lower
Level of Normal (LLN). A central pathology review
was performed by a single pathologist to ensure histo-
logical subtype. Subtyping was done according to the
WHO 2004 classiﬁcation. Patients were excluded if their
diagnosis of renal cell carcinoma (RCC) was uncon-
ﬁrmed. Untreated patients with locally advanced or met-
astatic disease, referred for systemic treatment were also
registered. Data on patients with mRCC not referred for
oncological treatment were not available.
2.2. Treatment regimens
Treatment options included sunitinib, sorafenib,
temsirolimus, everolimus, subcutaneous interferon-a or
interleukin-2 in combination with interferon-a, or
protocol treatment with dendritic cell vaccination,
sorafenib, subcutaneous interleukin-21, subcutaneous
interferon-a ± subcutaneous interleukin-2 and ﬂuoro-
uracil or subcutaneous interleukin-2 in combination
with interferon-a ± bevacizumab. Treatment choice
was decided by the local treating physician according
to national guidelines. Standard treatments were given
with standard dosing and schedules according to regula-
tory approvals. Trial results from treatment with inter-
leukin-21, sorafenib, dendritic cell vaccination,
interferon-a ± interleukin-2 and ﬂuorouracil have been
published previously [6–9].
2.3. Statistical analysis
OS was deﬁned as time from ﬁrst day of each treat-
ment line until death of any cause and analysed accord-
ing to validated prognostic factors [10,11], number of
treatment lines received and year of treatment start.
OS for untreated patients was calculated from the date
of metastatic disease until the date of death. Patients
alive at the end of study or emigrated were censored (last
follow up was 2012-10-31). PFS was not analysed due to
lack of central radiological review. Time to treatment
failure (TTF) was deﬁned from the ﬁrst day on each
treatment line until the date of treatment discontinua-
tion due to adverse events, patients request, locally
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assessed progression, death or other reasons. For
patients completing the scheduled immunotherapy treat-
ment, TTF was registered at date of progression
(assessed locally), death or beginning of a new treatment
line. Patients were censored if they emigrated or were
alive at the end of study (2010-12-31). OS and TTF were
calculated using the Kaplan–Meier method and median
follow up time with the reverse Kaplan–Meier method.
Diﬀerences in distributions were tested with the Chi-
square test. Missing values were handled with case-dele-
tion method. Association between prognostic factors,
treatment start year, number of treatment lines received
and OS were tested with log-rank test and a signiﬁcance
level of P 6 0.05 was chosen as an entry point for the
multivariate analysis using Cox proportional hazards
model. Statistical analyses were performed using R ver-
sion 2.14.0. (2011 The R Foundation for Statistical
Computing).
2.4. Ethics
The study was approved by the Danish Health
Authorities, the Danish Research Ethics Committee
and the Danish Data Protection Agency. The study
was registered with ClinicalTrials.gov NCT01339962.
3. Results
3.1. Patient characteristics
Overall, 1049 patients were identiﬁed of which 744
patients received ﬁrst line treatment from 2006 to
2010. Seven-hundred-and-ﬁfty-nine patients received
ﬁrst line treatment but 15 (2%) patients were excluded
after the central pathology review due to a diagnosis
other than RCC. Patient characteristics of the 744
patients are listed in Table 1.
Three-hundred-and-seven (41%) patients received
immunotherapy and 437 (59%) received targeted ther-
apy as ﬁrst line treatment. Five-hundred-and-eighty-
seven (79%) patients had an Eastern Cooperative Oncol-
ogy Group PS of 0–1. A total of 457 (61%) patients had
undergone a nephrectomy of which 21 (3%) patients
underwent nephrectomy following ﬁrst line treatment.
The histological subtypes were clearcell (612 patients,
82%), chromofobe (16 patients, 2%), papillary type 1
(30 patients, 4%), papillary type 2 (39 patients, 5%), col-
lecting ducts (6 patients, 1%), mucinous tubular and
spindle cell (3 patients, <1%) and unclassiﬁed (27
patients, 4%). Specimens from 11 (1%) patients could
not be retrieved. The distribution of patients according
to Hengs classiﬁcation showed a high proportion
(39%) in the poor prognostic group. One-hundred-
and-twenty-nine (17%) patients were still on treatment.
Treatment was mainly discontinued due to progressive
disease (41%), side-eﬀects (11%), and decline in PS
(10%).
The patient populations commencing therapy in 2006
and 2010 had no statistically diﬀerent distribution of
well-established prognostic factors, except more patients
had presence of brain metastases in 2010 than 2006 (7%
versus 2%) and fewer patients had elevated calcium in
2010 compared to 2006 (13% versus 46%).
3.2. Untreated patients
Three-hundred-and-ﬁve patients were referred but
did not receive systemic treatment with only 11 (4%)
patients being alive at last follow up and two (1%)
patients emigrated (Supplementary Table 1). Forty-ﬁve
(15%) patients had a PS of 0–1. It was not possible to
estimate Hengs prognostic group for 99 patients (32%)
mostly due to lack of blood samples, but there were as
many as 183 (60%) patients in the poor prognosis group.
Poor PS was the main reason for not receiving systemic
treatment (171 patients, 56%) while patient request and
death before treatment start accounted for 50 (16%) and
44 (14%) patients, respectively. The main reason for not
receiving treatment for patients in Hengs good and
intermediate risk groups was patient request (40%, data
not shown).
3.3. Treatment regimens
The distribution of patients per year and per drug for
ﬁrst line treatment is listed in Table 2a. An increased
number of patients was referred between 2006 and
2010 (P = 0.0492). The proportion of patients receiving
ﬁrst line treatment increased signiﬁcantly from 64% in
2006 to 75% in 2010 (P = 0.0188). The proportion
of patients receiving targeted therapy as ﬁrst line
treatment increased from 22% in 2006 to 75% in 2010
(P < 0.0001).
During the study period 273 (37%) of the 744 patients
received second line treatment and 91 (12%), 29 (4%), 10
(1%) and 3 (<1%) patients received third, fourth, ﬁfth
and sixth line treatment, respectively (Table 2b). In
2006 20% patients received second line treatment com-
pared to 40% patients in 2010 (P = 0.0104). Over the
years, a higher proportion of patients received addi-
tional treatment lines. 50% of the patients who received
second line treatment continued on third line treatment
in 2010 compared to 13%, 40% and 39% in 2007, 2008
and 2009, respectively. There was a similar tendency
over time for fourth, ﬁfth and sixth line treatments
although the patient numbers were low. Cytokines and
sunitinib were the most preferred treatment choices in
ﬁrst line treatment followed by sorafenib and sunitinib
in second and third line. Everolimus was predominantly
used in third and fourth line and temsirolimus was
rarely used (Supplementary Table 2).
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Table 1
Characteristics of Danish patients treated for mRCC by the period of treatment.
Variable First line 2006–2010 2006 2010 P valuea
Total number of patients (%) 744 (100) 113 (100) 163 (100)
Emigrated (%) 4 (1) 1 (1) 1 (1)
Median age (IQR) 62 (57–69) 60 (53–67) 64 (58–71) 0.0779b
Sex (male, %) 514 (69) 80 (71) 114 (70) 0.8781
PS 0.3701c
0 (%) 295 (40) 41 (36) 70 (43)
1 (%) 292 (39) 52 (46) 62 (38)
2 (%) 126 (17) 15 (13) 24 (15)
3 (%) 10 (1) 0 (0) 5 (3)
NA (%) 21 (3) 5 (4) 2 (1)
Median KPS (IQR) 90 (80–100) 90 (80–100) 90 (80–100)
KPS NA (%) 33 (4) 10 (9) 2 (1)
Heng 0.5348
Favourable (%) 79 (11) 13 (12) 25 (15)
Intermediate (%) 367 (49) 50 (44) 78 (48)
Poor (%) 289 (39) 47 (42) 60 (37)
NA (%) 9 (1) 3 (3) 0 (0)
Hgb < LLN (%) 366 (49) 58 (53) 85 (52) 0.925
NA (%) 3 (<1) 3 (3) 0 (0)
LDH > 1.5 times ULN (%) 73 (10) 11 (10) 20 (13) 0.579
NA (%) 17 (2) 6 (5) 3 (2)
Platelets > ULN (%) 208 (28) 20 (18) 43 (26) 0.1148
NA (%) 4 (1) 3 (3) 0 (0)
Neutrophils > ULN (%) 225 (31) 29 (26) 50 (31) 0.441
NA (%) 8 (1) 3 (3) 0 (0)
Ca2+ > ULN (%) 164 (23) 50 (46) 20 (13) <0.0001
NA (%) 16 (2) 4 (4) 3 (2)
Nephrectomy performed (%) 457 (61) 64 (56) 108 (66) 0.1048
Histology 0.8488
Clearcell (%) 612 (82) 90 (80) 134 (82)
Non-clearcell (%) 121 (16) 20 (18) 28 (17)
NA (%) 11 (1) 3 (3) 1 (1)
Less than 1 year from diagnoses (%) 555 (75) 79 (70) 121 (74) 0.4293
CNS metastases present (%) 52 (7) 2 (2) 12 (7) 0.0374
Liver metastases present (%) 157 (21) 22 (19) 32 (20) 0.9732
Metastatic sites 0.2245
1–2 (%) 369 (50) 59 (52) 73 (45)
More than 2 (%) 375 (50) 54 (48) 90 (55)
First line treatment
IL2/Interferon-alfa regimens (%) 304 (41) 86 (76) 40 (25)
Dendritic cell vaccination (%) 3 (<1) 2 (2) 1 (1)
Sorafenib (%) 67 (9) 24 (21) 4 (2)
Sunitinib (%) 364 (49) 1 (1) 112 (69)
Temsirolimus (%) 3 (<1) 0 (0) 3 (2)
Everolimus (%) 3 (<1) 0 (0) 3 (2)
Reason for treatment failure
Progression (%) 306 (41) 65 (58) 33 (20)
Death (%) 61 (8) 9 (8) 10 (6)
Patient request (%) 47 (6) 9 (8) 9 (6)
Side eﬀects (%) 85 (11) 9 (8) 16 (10)
Decline in performance status (%) 77 (10) 13 (12) 15 (9)
Other (%) 39 (5) 5 (4) 2 (1)
mRCC, metastatic renal cell carcinoma; IQR, interquartile range; PS, performance status; NA, not applicable; KPS, Karnofsky performance
status; Hgb, haemoglobin; LLN, lower level of normal; LDH, lactate dehydrogenase; ULN, Upper Level of Normal; Blood samples below or
above levels are given as a proportion of the available samples.
a Chi-square test between 2006 and 2010.
b For age of 63 years and above or below 63 years.
c For PS of 1 and below or above 1.
556 A.V. Soerensen et al. / European Journal of Cancer 50 (2014) 553–562
3.4. Survival analysis
One-hundred-and-thirty-seven (18%) patients were
alive at last follow up. Four (1%) patients were censored
due to emigration. Median follow up time for OS was
49.1 months (range: 2.0–81.8). Median OS for treated
patients increased signiﬁcantly from 11.5 months in
2006 to 17.2 months in 2010 (P = 0.0435; Table 3 and
Fig. 1). Median OS for Hengs favourable, intermediate
and poor risk groups were 33.4, 18.6 and 5.8 months,
respectively. A signiﬁcant improvement in median OS
between 2006 and 2010 was observed for the favourable
risk group (27.8 months versus not reached, P = 0.045).
There were a tendency for improved OS in the interme-
diate risk group but it was not signiﬁcant. Median OS
was almost unchanged for the poor risk group
(Fig. 2A–D). Median OS for untreated patients was
3.0 months (95% CI, 2.6–3.8) with no signiﬁcant change
from 2006 to 2010 (P = 0.676; Supplementary Table S3).
Median follow up time for TTF was 23.5 months
(range: 0.1–55.1) and 129 (17%) patients were censored
at the end of study. We observed the median TTF for
ﬁrst line treatment improved from 3.1 months (95%
CI, 2.9–4.2) in 2006 to 4.9 months (95% CI, 3.8–6.4) in
2010 (P = 0.0058; Supplementary Table S3).
3.5. Univariate analysis
PS, prior nephrectomy, time from diagnose to treat-
ment start, presence of CNS and liver metastases, treat-
ment year 2006 compared to 2010, number of metastatic
sites, histology, Hengs risk groups, haemoglobin, plate-
lets, neutrophils, calcium and LDH were all indicators
of OS (Table 3). Patients that received more than two
treatment lines had a signiﬁcantly longer OS from the
start of ﬁrst line treatment compared to patients that
received 1–2 lines of treatment (27.8 versus 11.5 months,
P < 0.0001).
3.6. Multivariate analysis
The multivariate analysis (Table 4) was based on 688
patients; 56 patients were deleted due to missing values.
The model was corrected for interaction between PS and
the number of treatment lines received. Haemoglobin
below LLN, LDH 1.5 times above ULN, platelets and
neutrophils above ULN, non-clearcell histology, less
than 1 year from diagnose to treatment start and more
than 2 metastatic sites were signiﬁcantly associated with
shorter OS for ﬁrst line treatment. Hypercalcaemia was
borderline signiﬁcant. Patients who received more than
two treatment lines had a longer OS compared to 1 or
2 treatment lines. Patients in PS 0–1 had a signiﬁcant
longer OS if they received 3–6 treatment lines compared
to 1 or 2 treatment lines (HR 0.76, 95% CI, 0.58–0.99;
P = 0.0397). Patients in PS 2–3 also had a signiﬁcantly
longer OS if they received 3–6 treatment lines compared
to 1 or 2 treatment lines (HR 0.19, 95% CI, 0.06–0.60;
P = 0.0051). Patients who received 1 or 2 treatment lines
and were in PS 0–1 had a longer OS compared to
Table 2
(a) Drug distribution for ﬁrst line treatment per year; (b) number of patient distributed on each treatment line per year, in Danish mRCC patients
between 2006 and 2010.
2006 2007 2008 2009 2010 2006–2010 P value
a.
First line
Immunotherapy (%) 88 (78) 64 (45) 69 (43) 45 (27) 41 (25) 307
Cytokines 86 64 69 45 40 304
Dendritic cell vaccination 2 0 0 0 1 3
Targeted therapy (%) 25 (22) 77 (55) 93 (57) 120 (73) 122 (75) 437 <0.0001a
Everolimus 0 0 0 0 3 3
Sorafenib 24 28 10 1 4 67
Sunitinib 1 49 83 119 112 364
Temsirolimus 0 0 0 0 3 3
Untreated patients 64 74 59 55 53 305
Total referred patients 177 215 221 220 216 1049 0.0492a
Treatment proportion 64% 66% 73% 75% 75% 71% 0.0188
2006 2007 2008 2009 2010 2006–2010b P value
b.
First line (%) 113 (100) 141 (100) 162 (100) 165 (100) 163 (100) 744 (100)
Second line (%) 23 (20) 56 (40) 52 (32) 76 (46) 66 (40) 273 (37) 0.0104a
Third line (%) 0 (0) 7 (13) 21 (40) 30 (39) 33 (50) 91 (12)
Fourth line (%) 0 (0) 0 (0) 4 (19) 10 (33) 15 (45) 29 (4)
Fifth line (%) 0 (0) 0 (0) 0 (0) 1 (10) 9 (60) 10 (1)
Sixth line (%) 0 (0) 0 (0) 0 (0) 0 (0) 3 (33) 3 (<1)
mRCC, metastatic renal cell carcinoma.
a Between 2006 and 2010.
b First line patients receiving additional treatment lines.
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Table 3
Univariate analysis of predictors of overall survival for Danish patients treated for mRCC between 2006 and 2010.
Risk factor N % % Alive Median OS 95% CI P value
Age 0.467
P63 390 52 18 14.1 11.7–15.7
<63 354 48 20 13.8 11.5–17.7
Gender 0.693
Male 514 69 20 13.5 11.5–15.3
Female 230 31 17 15.3 12.6–18.4
Heng <0.0001
Favourable 79 11 46 33.4 29.4–44.7
Intermediate 367 50 23 18.6 16.7–21.4
Poor 289 39 6 5.8 5.0–7.2
PS <0.0001
0–1 587 81 22 17.2 15.3–19.2
>1 136 19 6 4.0 3.1–5.8
Received treatment lines <0.0001
1–2 653 88 20 11.5 10.1–13.5
3–6 91 12 14 27.8 25.7–33.1
Haemoglobin <0.0001
<LLN 366 49 10 8.2 7.1–10.0
>LLN 375 51 28 23.2 20.1–26.9
LDH <0.0001
<1.5 ULN 654 90 22 16.1 14.3–18.0
>1.5 ULN 73 10 0 3.6 3.1–4.5
Platelets <0.0001
<ULN 532 72 23 17.8 15.4–19.8
>ULN 208 28 8 8.1 6.7–10.6
Neutrophils <0.0001
<ULN 511 69 25 18.1 16.3–20.4
>ULN 225 31 7 6.5 5.2–8.2
Hypercalcaemia 0.0005
No 564 77 22 15.3 13.8–17.8
Yes 164 23 10 9.2 7.1–14.0
Nephrectomy performed <0.0001
Yes 457 61 25 18.3 15.8–20.9
No 287 39 10 9.1 7.5–11.5
Clearcell histology <0.0001
Yes 612 83 21 15.3 14.0–17.7
No 136 17 12 6.7 5.2–11.1
Less than 1 year from diagnose <0.0001
Yes 555 75 15 11.5 10.0–13.5
No 189 25 30 26.8 23.2–31.1
CNS metastases 0.0064
Yes 52 7 15 7.6 4.0–12.7
No 692 93 19 14.7 13.4–16.2
Liver metastases <0.0001
Yes 157 21 13 8.1 6.5–10.6
No 587 79 21 15.8 14.2–17.9
Metastatic sites <0.0001
1–2 369 50 25 17.9 15.4–20.8
More than 2 375 50 13 10.7 8.9–12.6
Start year
2006 113 15 10 11.5 9.1–14.8
2007 141 19 11 14.3 10.8–18.2 0.284a
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patients in PS 2–3 (HR 0.64, 95% CI, 0.51–0.80;
P < 0.0001). Treatment start year 2008, 2009 and 2010
compared to 2006 were all independently associated
with longer OS.
4. Discussion
This study is to our knowledge the ﬁrst complete
national assessment of the implementation of targeted
therapy for patients with mRCC. We observed a signif-
icant increase in the number of patients referred for
treatment; a signiﬁcant increase in patients receiving
treatment; a signiﬁcant increase in additional treatment
lines received; a change from immunotherapy to tar-
geted therapy and an increased OS for patients receiving
treatment whereas survival rate for untreated patients
remained unchanged. These data emphasise a new era
for patients with mRCC.
Large randomised trials have shown an improved PFS
for patients treated with targeted agents, but only temsi-
rolimus has demonstrated a signiﬁcant OS beneﬁt [1–5].
Lack of improved OS in clinical trials could be explained
by confounding due to cross-over or treatment eﬀects
from subsequent treatment lines. Retrospective studies
[11,12] and expanded access programmes [9,13,14] have
indicated that there is a survival beneﬁt for ‘real-world’
patients, however, these studies contained a mix of ﬁrst,
second and third line patients. Large epidemiological reg-
istry-based studies [15,16] have shown an improved OS,
but these results were based on either a mix of patients
with RCC and mRCC or lack of information regarding
the fraction of treated patients. Poprach et al. [17]
reported results from theCzechRepublic nationalmRCC
database, but this study omitted patients receiving immu-
notherapy and was therefore not a complete national
cohort. Our study is the ﬁrst report to document an
improved OS in a complete national cohort of treated
patients with conﬁrmed mRCC.
Our study is also the ﬁrst to provide detailed informa-
tion regarding sequential therapies and histological sub-
type in a complete national cohort. The proportion of
patients receiving ﬁrst line and subsequent treatment
lines increased signiﬁcantly during the study period. Part
of the increase in referred patients could be caused by
the general increase in incidence rate of renal cell
carcinoma. Approximately only one third of the patients
received an additional treatment line after failure of the
previous one. This proportion, however, increased sig-
niﬁcantly from 20% in 2006 to 40% in 2010 for second
line treatment; similar to Heng et al. [18] where approx-
imately 40% of anti-VEGF-treated patients received fur-
ther treatment. Unfortunately, there is still a high
proportion of real-life patients that are not able to
receive further treatment despite the availability of sev-
eral new treatment options.
During implementation of new treatment strategies it
is expected that there will be a lag period before an impact
on OS is seen.We observed a tendency towards improved
year-by-year OS from 11.5 months in 2006 where the ﬁrst
Danish patients received targeted therapy to 17.2 months
in 2010 where the majority received targeted therapy and
we suggest that this improvement was caused by the new
treatment opportunities. Other factors may have aﬀected
the outcome, e.g. improved supportive care, although one
would then have expected to ﬁnd a similar increase in OS
for untreated patients. The signiﬁcant prognostic factors
from the multivariate analysis were in accordance with
previous ﬁndings [10,11]. Moreover; the improved sur-
vival rate is not explained by a changed distribution in
validated [19] prognostic factors according to Heng as
these were evenly distributed between patients starting
treatment in 2006 and 2010. Signiﬁcantly fewer patients
Table 3 (continued)
Risk factor N % % Alive Median OS 95% CI P value
2008 162 22 18 13.4 10.7–17.9 0.208a
2009 165 22 20 14.7 12.4–18.2 0.205a
2010 163 22 33 17.2 13.5–23.1 0.0435a
mRCC, metastatic Renal Cell Carcinoma; N, number; OS, overall survival; CI, conﬁdence interval; PS, performance status; LLN, lower level of
normal; LDH, lactate dehydrogenase; ULN, Upper Level of Normal.
a Compared to 2006.
Fig. 1. Kaplan–Meier estimates of overall survival in Danish mRCC
patients receiving treatment.
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had CNS metastases in 2006 compared to 2010 possibly
reﬂecting that these patients were not referred to our
departments due to the relative contraindication for
immunotherapy. The diﬀerence in the distribution of
hypercalcaemia likely reﬂects lead time bias as more
patients were treated before hypercalcaemia developed
Table 4
Multivariate analysis of predictors of overall survival for Danish patients treated for mRCC between 2006 and 2010. N = 688a
Risk factor Hazard ratio 95% CI P value
PS 0–1 and 3–6 versus 1–2 treatment lines 0.76 0.58–0.99 0.0397
PS 2–3 and 3–6 versus 1–2 treatment lines 0.19 0.06–0.60 0.0051
1–2 treatment lines and PS 0–1 versus PS 2–3 0.64 0.51–0.80 <0.0001
Haemoglobin below LLN 1.83 1.51–2.23 <0.0001
LDH above 1.5 ULN 2.75 2.06–3.67 <0.0001
Platelets above ULN 1.24 1.01–1.53 0.0404
Neutrophils above ULN 1.64 1.35–1.99 <0.0001
Hypercalcaemia 1.22 0.99–1.50 0.0594
No nephrectomy performed 1.17 0.97–1.42 0.1091
Clearcell histology 0.63 0.50–0.79 <0.0001
Less than 1 year from diagnose 1.36 1.07–1.72 0.0106
CNS metastases 1.33 0.94–1.87 0.1028
Liver metastases 1.11 0.90–1.38 0.3248
More than 2 metastatic sites 1.25 1.05–1.50 0.0132
Startyear 2007 versus 2006 0.86 0.64–1.14 0.2897
Startyear 2008 versus 2006 0.74 0.55–0.99 0.0415
Startyear 2009 versus 2006 0.72 0.54–0.96 0.0277
Startyear 2010 versus 2006 0.63 0.47–0.86 0.0035
mRCC, metastatic renal cell carcinoma; N, number; CI, conﬁdence interval; PS, performance status; LLN, lower level of normal; LDH, lactate
dehydrogenase; ULN, Upper Level of Normal.
a 56 patients deleted due to missing values. The model was corrected for interaction between performance status and numbers of treatment lines
received.
Fig. 2. Kaplan–Meier estimates of overall survival (OS) over time for Hengs prognostic groups for Danish patients treated for mRCC. (A) Overall
survival for Hengs favourable, intermediate and poor risk group were 33.4, 18.6 and 5.8 months, respectively. (B) Overall survival for Hengs good
prognosis group over time; 2006 median OS 27.8 months (95% CI, 18.9-NA) versus 2010 median OS not reached (95% CI, 33.0-NA). (C) Overall
survival for Hengs intermediate prognosis group over time; 2006 median OS 13.4 months (95% CI, 11.0–27.1) versus 2010 median OS 18.6 months
(95% CI, 14.8–26.0). (D) Overall survival for Hengs poor prognosis group over time; 2006 median OS 5.2 months (95% CI, 3.7–9.4) versus 2010
median OS 5.7 months (95% CI, 4.3–10.7).
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due to knowledge of better treatment options in 2010
compared to 2006. The apparently low nephrectomy rate
may reﬂect reluctance to perform major surgery in
patients with many risk factors in the absence of random-
ised trials supporting debulking nephrectomy in the era of
targeted therapy. A similar nephrectomy-rate has been
published from Sweden [16]. The multivariate analysis
demonstrated that patients who received more than two
treatment lines had a longer OS both for patients in good
and poor PS. Treatment year 2008, 2009 and 2010 com-
pared to 2006 were independently associated with longer
OS which may be explained by better patient selection to
relevant treatment or by other unknown confounding
factors. It should be noted that 39% were in Hengs poor
risk group and 16% had non-clearcell histology which
has recently been associated with an inferior outcome
[20]. Nevertheless, we were able to demonstrate a survival
beneﬁt from therapy in the complete cohort of patients.
Our results suggest that the improved OS over the
years reﬂects the availability of more treatment options
over time for use in sequential treatment as shown by
the multivariate analysis that demonstrates a signiﬁcant
improved OS for patients receiving more than two treat-
ment lines. We therefore suggest that the OS beneﬁt
observed in this heterogeneous cohort of patients is
the result of the total amount of consecutive treatments,
and not restricted to the individual treatments per se.
In 2009, the Danish health authorities implemented
structural changes to speed up the diagnostic process
and established a fast track for the treatment of cancer
nationally. The present study does not allow for assess-
ment of such changes as the impact of these initiatives
will have a lag period. Nevertheless, the high proportion
of referred but untreated patients and their dismal med-
ian OS of only 3.0 months from the date of metastatic
disease highly emphasise the need for initiatives to
reduce time for diagnostic work-out and referrals.
There are limitations to our study due to the retro-
spective design. Importantly the survival data are com-
plete due to the unique Danish social security number
system.
5. Conclusion
This is the ﬁrst retrospective study to document that
the implementation of targeted therapy has resulted in
improved treatment rates and overall survival in a com-
plete national cohort of treated patients with conﬁrmed
mRCC.
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